Gene Editing Transforms Teen's Life by Reversing Thalassemia Symptoms

A 16-year-old girl named Vian has experienced a life-altering transformation thanks to a pioneering gene editing therapy that has reversed the debilitating symptoms of thalassemia, a serious blood disorder. Vian, who was born with the condition, previously endured monthly blood transfusions to manage her thalassemia, which affects hemoglobin and the transport of oxygen throughout the body, often leaving her short of breath and lacking appetite. Now, she no longer requires these transfusions.

"My whole life's different now. It's changed so much," Vian stated, reflecting on the significant impact of the treatment. The therapy, offered at three children's hospitals in the UK, targets patients with thalassemia or sickle cell disease. Vian, from Coventry, was among the first young people to receive this innovative treatment.

Her own stem cells were collected, genetically edited in a laboratory, and then returned to her in December following chemotherapy. She has since made a full recovery. "It's much easier for me now. I always have energy to do stuff," Vian explained. "I'm like, ‘mum let's go out’. Before, I would just sleep, always tired."

Inspired by her extensive experiences with medical staff, Vian has begun studying health and social care in college, aspiring to become a nurse. "I have more options now. Before, I couldn't do most things other kids could," she added. "I usually sat out of PE. I really love PE, but I couldn't do that."

Dr. Sarah Lawson, a consultant hematologist, described the treatment as a "functional cure," meaning the disease itself isn't eradicated but the problematic symptoms are eliminated. The process involves collecting stem cells, editing them in a lab to enhance the production of fetal or baby hemoglobin, and then reinfusing them into the patient. For thalassemia patients, this can eliminate the need for transfusions, while for sickle cell disease patients, it can negate the complications associated with the condition.

"When I was at medical school... I remember learning a little bit about gene therapy and it being talked about then. And for it now to be a reality 20-odd years later is incredible," Dr. Lawson commented.

Another patient, 14-year-old JoelSamuel from Oldbury, is at the beginning of his treatment journey for sickle cell disease, a condition known for causing excruciating pain and fatigue. His stem cells were recently collected at Birmingham Children's Hospital and will undergo editing before being returned to him after chemotherapy in about six months. JoelSamuel hopes the treatment will enable him to participate in sports without falling ill, a current limitation.

"I get tired and then the next day I get sick and I won't be able to go to school," he said, expressing initial nervousness but also hope for the treatment's success. "I think it's good to make me better, so I can go and do stuff that takes my energy."

JoelSamuel's parents, Alfred and Juliet, shared their optimism. "There are a few patients that have been on it, mainly with thalassemia instead of sickle cell. So we are hoping that we might get the same effects from it," Alfred said, hoping his son might one day play football. Juliet expressed her eagerness to see him "doing the normal things that everybody does at his age."

Vian offered words of encouragement to JoelSamuel: "Imagine all the things you can do while being healthy again. I think you can do it, I did it and so can you. I know it's going to be really hard and the trauma and everything, the nurses, the medicine, everything, but it's worth it."

Vian has since been discharged from the hospital, her life significantly improved by the advancements in gene editing technology.